Scleroderma Genomics and Health Disparities Unit Tables

Table 1. Clinical Manifestations of scleroderma patients in the GRASP cohort (Morgan, Gourh, et al, Medicine 2017)
	Diffuse Scleroderma	Telangiectasia	Calcinosis	Pulmonary^∥† Fibrosis	FVC% pred^† ≤70	Pulmonary^¶† Hypertension	Scleroderma Renal Crisis
Age at onset	0.99 (0.97-1.00)	0.99 (0.98-1.01)	1.00 (0.98-1.01)	1.00 (0.99-1.02)	1.00 (0.98-1.02)	1.02^‡ (1.00-1.04)	1.01 (0.98-1.05)
Disease duration	0.93 (0.90-0.95)	1.04 (1.02-1.07)	1.05 (1.02-1.08)	1.02 (0.99-1.05)	1.01 (0.98-1.04)	1.06 (1.03-1.09)	1.01 (0.96-1.07)
Male sex	1.53 (0.91-2.57)	0.89 (0.56-1.42)	0.74 (0.39-1.39)	0.80 (0.47-1.36)	1.37 (0.77-2.42)	1.53 (0.87-2.69)	1.81 (0.75-4.37)
Diffuse SSc subtype	–	1.14 (0.78-1.67)	1.36 (0.82-2.24)	0.63 (0.41-0.98)	0.91 (0.58-1.14	0.59 (0.37-0.93)	2.45 (0.92-6.47)
ACA	0.14 (0.05-0.38)	1.47 (0.69-3.12)	0.68 (0.25-1.86)	0.45 (0.20-1.05)	0.88 (0.38-2.02)	1.52 (0.71-3.26)	§
Topo I	1.67 (1.08-2.58)	0.77 (0.52-1.15)	1.57 (0.96-2.57)	2.14 (1.38-3.31)	2.05 (1.26-3.33)	1.29 (0.79-2.10)	0.53 (0.19-1.49)
RNA Pol III	2.54 (1.36-4.75)	0.43 (0.24-0.75)	1.29 (0.65-2.56)	1.00 (0.54-1.84)	0.94 (0.50-1.78)	1.22 (0.61-2.45)	2.88 (1.20-6.94)
Smoking status	–	–	–	1.41 (0.93-2.14)	1.58 (1.01-2.46)	1.19 (0.75-1.86)	–

Table 2. Pathway analysis of the candidate genes in the GRASP cohort (Gourh et al, Arthritis and Rheumatology 2018
Ingenuity Pathway	P†	Corrected P‡
AII SSc patients versus controls
Hepatic fibrosis/hepatic stellate cell activation	2.09 x 10^-6	1.95 x 10^-4
Melatonin degradation III	0.005	0.22
Coagulation system	0.01	0.29
Complement system	0.01	0.29
Atherosclerosis signaling	0.02	0.34
Diffuse SSc subset of Patients versus controls
Hepatic fibrosis/hepatic stellate cell activation	2.27 x 10^-6	2.14 x 10^-4
Melatonin degradation III	0.005	0.22
Coagulation system	0.01	0.29
Complement system	0.01	0.29
Atherosclerosis signaling	0.02	0.36